Convergent animal and human evidence suggests the activin/inhibin pathway to be involved in antidepressant response
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Despite the overt need for improved treatment modalities in depression, efforts to develop conceptually novel antidepressants have been relatively unsuccessful so far. Here we present a translational approach combining results from hypothesis-free animal experiments with data from a genetic association study in depression. Comparing genes regulated by chronic paroxetine treatment in the mouse hippocampus with genes showing nominally significant association with antidepressant treatment response in two pharmacogenetic studies, the activin pathway was the only one to show this dual pattern of association and therefore selected as a candidate. We examined the regulation of activin A and activin receptor type IA mRNA following antidepressant treatment. We investigated the effects of stereotaxic infusion of activin into the hippocampus and the amygdala in a behavioural model of depression. To analyse whether variants in genes in the activin signalling pathway predict antidepressant treatment response, we performed a human genetic association study. Significant changes in the expression of genes in the activin signalling pathway were observed following 1 and 4 weeks of treatment. Injection of activin A into the hippocampus exerts acute antidepressant-like effects. Polymorphisms in the betaglycan gene, a co-receptor mediating functional antagonism of activin signalling, significantly predict treatment outcome in our system-wide pharmacogenetics study in depression. We provide convergent evidence from mouse and human data that genes in the activin signalling pathway are promising novel candidates involved in the neurobiogical mechanisms underlying antidepressant mechanisms of action. Further, our data suggest this pathway to be a target for more rapid-acting antidepressants in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Binder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977
Self-citationSerretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001926 · Cited by 529
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450 · cited 1×
“suggesting that alternative pharmacogenetic strategies need to be established.(10,11) In this study, we use a conceptually different approach by”
MethodHow can drug discovery for psychiatric disorders be improved?
Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., et al. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2217 · Cited by 240
The Neuronal Transporter Gene SLC6A15 Confers Risk to Major Depression
Kohli, M. A., Lucae, S., Saemann, P. G., Schmidt, M. V., Demirkan, A., Hek, K., Czamara, D., Alexander, M., Salyakina, D., Ripke, S., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.005 · Cited by 228
Self-citationMachado-Vieira, R., Salvadore, G., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0610 · Cited by 195
Cited by
The role of 5-HT receptors in depression
Yohn, C. N., Gergues, M. M., & Samuels, B. A. (2017) · Molecular Brain · doi:10.1186/s13041-017-0306-y · Cited by 485
Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications
Fabbri, C., & Serretti, A. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0594-9 · Cited by 84
TGF-β/Smad Signalling in Neurogenesis: Implications for Neuropsychiatric Diseases
Hiew, L.-F., Poon, C.-H., You, H.-Z., & Lim, L.-W. (2021) · Cells · doi:10.3390/cells10061382 · Cited by 71
“Furthermore, Smad3 signalling in neurones and astroglia were found to differentially regulate dendritic spine growth [56], whereas its inhibition leads to increased susceptibility to neuronal apoptosis [57], potentially increasing the risk of Parkinson’s disease [25] and neurodegeneration [26].”
BackgroundActivin Signaling in the Pathogenesis and Therapy of Neuropsychiatric Diseases
Link, A. S., Zheng, F., & Alzheimer, C. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00032 · Cited by 38
Metadata
- Authors
- Ganea, K., Menke, A., Schmidt, M. V., Lucae, S., Rammes, G., Liebl, C., Harbich, D., Sterlemann, V, Storch, C., Uhr, M., Holsboer, F., Binder, E. B., Sillaber, I., & Müller, M. B.
- Venue
- Translational Psychiatry
- Published
- 2012-10-23
- Volume
- 2
- Issue
- 10
- Pages
- e177-e177
- ISSN
- 2158-3188 (ISSN-L)
- OpenAlex
- W2086524546
- Cited by
- 31
- References
- 7
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Convergent animal and human evidence suggests the activin/inhibin pathway to be involved in antidepressant response. https://app.cochat.ai/papers/10.1038/tp.2012.104
- The paper
- Ganea, K., Menke, A., Schmidt, M. V., Lucae, S., Rammes, G., Liebl, C., Harbich, D., Sterlemann, V, Storch, C., Uhr, M., Holsboer, F., Binder, E. B., Sillaber, I., & Müller, M. B. (2012). Convergent animal and human evidence suggests the activin/inhibin pathway to be involved in antidepressant response. Translational Psychiatry. https://doi.org/10.1038/tp.2012.104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.